C1213 attenuates Aβ-induced cognitive deficits and reduces Aβ plaque volume in CRND8 transgenic mice. (A–C) An object location task was performed with Veh- and C1213-treated CRND8 mice. (A) Both treatment groups showed equivalent object exploration times in the test trial. (B) C1213-treated mice displayed preferential examination of the object moved to a novel location and (C) a significantly enhanced recognition index. (D–E) Immunohistochemical analysis of Aβ plaques in CRND8 mice. (D) Treatment with C1213 significantly reduced Aβ plaque volume while (E) plaque number remained unchanged. * P < 0.05; ** P < 0.01; *** P < 0.001. n.s., not significant.